

1
2
3 **CaMKII oxidation is a performance/disease trade-off in vertebrate evolution**
4

5 Qinchuan Wang¹, Erick O. Hernández-Ochoa², Meera C. Viswanathan¹, Ian D. Blum³, Jonathan
6 M. Granger¹, Kevin R. Murphy¹, An-Chi Wei⁴, Susan Aja^{5,6}, Naili Liu⁷, Corina M. Antonescu⁸,
7 Liliana D. Florea⁸, C. Conover Talbot Jr.⁹, David Mohr¹⁰, Kathryn R. Wagner^{3,7}, Sergi Regot¹¹,
8 Richard M. Lovering¹², Mark N. Wu³, Anthony Cammarato¹, Martin F. Schneider², Gabriel S.
9 Bever^{1,13}, Mark E. Anderson*¹

10
11 1 Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
12 2 Department of Biochemistry and Molecular Biology, University of Maryland School of
13 Medicine, Baltimore, MD, USA
14 3 Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA
15 4 Department of Electrical Engineering, Graduate Institute of Biomedical Electronics and
16 Bioinformatics, National Taiwan University, Taipei, Taiwan
17 5 Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD, USA
18 6 Center for Metabolism and Obesity Research, Johns Hopkins School of Medicine,
19 Baltimore, MD, USA
20 7 Center for Genetic Muscle Disorders, Kennedy Krieger Institute, Baltimore, MD, USA
21 8 Johns Hopkins Computational Biology Consulting Core, Baltimore, MD, USA
22 9 Institute for Basic Biomedical Sciences, Johns Hopkins School of Medicine, Baltimore,
23 MD, USA
24 10 Johns Hopkins School of Medicine Genetic Resources Core Facility
25 11 Department of Molecular Biology & Genetics, Johns Hopkins School of Medicine,
26 Baltimore, MD, USA
27 12 Department of Orthopaedics, University of Maryland School of Medicine, Baltimore,
28 MD, USA
29 13 Center for Functional Anatomy & Evolution, Johns Hopkins School of Medicine,
30 Baltimore, MD, USA

31
32 * Correspondence: Mark E. Anderson, MD, PhD, mark.anderson@jhmi.edu
33
34

35 **Reactive oxygen species (ROS) contribute to health and disease. CaMKII is a widely**
36 **expressed enzyme whose activation by oxidation of regulatory domain methionines (ox-**
37 **CaMKII) contributes to cardiovascular disease, asthma, and cancer. Here we integrate**
38 **comparative genomic and experimental data to show that CaMKII activation by ROS**
39 **arose more than half-a-billion years ago on the vertebrate stem lineage where it constituted**
40 **a bridge between ROS and increased intracellular Ca²⁺ release, exercise responsive gene**
41 **transcription, and improved performance in skeletal muscle. These enhancements to fight-**
42 **or-flight physiology were likely key in facilitating a well-evidenced shift in the behavioural**
43 **ecology of our immediate chordate ancestors, and, in turn, the evolutionary success of**
44 **vertebrates. Still, the ox-CaMKII innovation for augmenting performance must be**
45 **considered a critical evolutionary trade-off, as it rendered us more susceptible to common**
46 **and often fatal diseases linked to excessive ROS.**

47
48 The Ca²⁺- and calmodulin-dependent protein kinase II (CaMKII) is a multifunctional enzyme that
49 augments intracellular Ca²⁺ flux, and regulates gene transcription¹. CaMKII is initially activated
50 by binding calmodulin, but post-translational modifications²⁻⁵ of conserved regulatory domain
51 residues convert CaMKII into a Ca²⁺- and calmodulin-independent conformation by preventing
52 the regulatory domain from occluding the active site (Fig. 1a). These post-translational
53 modifications include autophosphorylation at threonine 287 (T287, numbered in accordance with
54 CaMKII γ isoform)^{4,5}, O-GlcNAcylation at serine 280 (S280)³, and oxidation at cysteine
55 281/methionine 282 (CM; CaMKII α) or methionine 281/282 (MM; CaMKII γ , δ and β)².
56 CaMKII activity using the oxidative pathway (ox-CaMKII) is elevated in tissues of patients with
57 cardiovascular diseases^{6,7}, human cancer cell lines⁸, and asthmatic human pulmonary
58 epithelium⁹, suggesting ox-CaMKII contributes to common human diseases. Mutant knock-in
59 mice where the MM module in CaMKII δ was replaced by ROS-resistant VV (valine 281/282)
60 mutations are protected against a range of diseases that involve elevated oxidative stress,
61 including stroke, cardiac arrhythmia, ischemia-reperfusion injury, sudden death, and asthma^{6,7,10-}
62 ¹³. Given its clinical relevance, we sought to better understand the biological role of ox-CaMKII
63 by exploring its evolutionary origins and functional implications.

64 65 **MM residues confer ROS sensitivity to CaMKII in vertebrates and invertebrates**

66 The phylogenetic distribution of ox-CaMKII supports the inference that an oxidation-sensitive
67 amino acid pair in the regulatory domain is a derived feature of vertebrates, one that emerged on
68 the vertebrate stem lineage sometime between approximately 570 and 480 million years ago (Fig
69 1b; Extended Data Fig. 1). This origin contrasts markedly with that of the T287 and S280
70 regulatory pathways. These appear to have evolved concurrent with CaMKII itself and are
71 features ancestral to all metazoans, antedating the CM module by an additional ~500 million
72 years (Fig 1b). The consistent expression among crown vertebrates of an oxidation-sensitive pair
73 at regulatory loci 281/282 indicates this vertebrate oxidative pathway has never been lost. It also
74 indicates that ox-CaMKII is likely integrated within functionally and evolutionarily beneficial
75 cascades, but at the cost of enhanced susceptibility to common, ROS-mediated diseases.

76
77 To test whether the MM module was sufficient to convert an invertebrate CaMKII into a ROS
78 sensor, we mutated the ROS-resistant VV residues in *Drosophila melanogaster* into MM
79 (Extended Data Fig. 2). *Drosophila melanogaster* is advantageous as a model, in part, because it
80 has only one *CaMKII* gene. We found that the *CaMKII*^{MM}/*CaMKII*^{MM} flies (referred to as MM
81 flies hereafter) showed a significantly higher mortality when fed sucrose solutions dosed with
82 paraquat, a ROS-inducing toxin¹⁴ (Fig. 1c). These results establish a phylogenetically justified
83 inference that the evolutionary appearance of these residues did confer ROS sensitivity through
84 CaMKII activity in our stem-vertebrate ancestors.

85
86 The vertebrate stem lineage was witness to a major shift in behavioural ecology that set the stage
87 for the modern (crown) vertebrate radiation and eventually our own evolutionary origin¹⁵. Out
88 was the sessile, filter-feeding existence that served our deuterostome ancestors well and that still
89 characterizes the adults of our closest living chordate relatives — the lancelets and tunicates. In
90 was the metabolically costly strategy of being an active marine predator. A large series of
91 structural innovations supported this dramatic transition by fundamentally altering the way in
92 which these stem vertebrates received, processed, and acted on environmental stimuli. A few

93 examples include: a prechordal head with complex organs of special sensation and a fully
94 differentiated forebrain, a cartilaginous internal skeleton, muscular pharyngeal arches supporting
95 advanced respiration, a more powerful heart pumping blood containing haemoglobin-rich red-
96 blood cells, and a sympathetic nervous system and elaborate endocrine glands supporting a fight-
97 or-flight physiological response. Many of these novel functional complexes were developmental
98 products of a newly evolved population of highly migratory and multipotent neural crest cells,
99 and, ultimately, the entire suite of derived vertebrate features may well owe its existence to a
100 greatly expanded genetic tool kit made available by one, and possibly, two full rounds of genome
101 duplication¹⁶. At some level, all of these innovations promote an increasing level of activity that
102 must be enacted through the skeletal (striated) musculature; so, it was with the physiology of
103 skeletal muscle that we tested for potential beneficial effects of ox-CaMKII.

104
105 CaMKII activity contributes to skeletal muscle function^{17,18}, so we hypothesized that gaining the
106 MM motif allowed ROS to enhance skeletal muscle performance through ox-CaMKII. We set
107 out to test whether MM residues could dynamically respond to ROS in muscle fibres to increase
108 CaMKII activity. To measure the dynamic change of CaMKII activity in muscle fibres, we
109 developed a fluorescent reporter that translocates from the nucleus to the cytosol in response to
110 increased activity of CaMKII (kinase translocation reporter, or KTR, Extended Data Fig. 3a and
111 b and Methods)¹⁹. We validated the reporter in RPE-1 cells by showing that it translocated into
112 the cytosol when the cells were treated by histamine (Extended Data Fig. 3c and d), which
113 transiently increased cytosolic Ca²⁺ concentration²⁰ (data not shown). This translocation was
114 enhanced by co-expressed exogenous CaMKII, and blunted by co-expressed kinase-dead
115 CaMKII mutant²¹ (CaMKII^{K43M}) and by the CaMKII-specific inhibitory protein CaMKIIN²²,
116 supporting that the KTR translocation was driven by CaMKII activity. The results show that the
117 cytosol/nuclear distribution of the KTR is a sensitive measurement of cellular CaMKII activity
118 (Extended Data Fig. 3e). To determine the role of MM residues for ROS-induced CaMKII
119 activity in muscle fibres, we developed a knock-in mouse where the MM residues of CaMKII γ
120 were replaced with VV (Extended Data Fig. 4a and 4b, homozygous *CaMKII γ ^{VV}/CaMKII γ ^{VV}*
121 mice are referred to as VV mice hereafter). We selected *Camk2g* as the background because we
122 found that CaMKII γ is the most abundant isoform in mouse skeletal muscle (Extended Data Fig.
123 5a). The knock-in mutation did not change the mRNA expression from the *Camk2g* gene
124 (Extended Data Fig. 5b). We introduced the CaMKII-KTR into the flexor digitorum brevis
125 (FDB) skeletal muscles of MM (referring to wild type or WT mice) and VV mice by
126 electroporating plasmids²³ encoding the reporter and isolated the FDB muscle fibres after KTR
127 was expressed (see Methods). We found that the increase of CaMKII activity in response to
128 electrical stimulation required the MM motif (Fig. 1d and e). Addition of the antioxidant N-
129 acetylcysteine (NAC) eliminated the rise in CaMKII activity in both VV and MM (WT) FDB
130 fibres in response to stimulation (Fig. 1d and e). The results showed that ROS contribute to the
131 activation of myofibre CaMKII, a process dependent on the MM module of CaMKII.

132 133 **Ox-CaMKII promotes exercise performance**

134 Based on our hypothesis that ox-CaMKII arose in vertebrates to enhance skeletal muscle
135 performance, we next asked whether loss of the MM residues affected exercise by testing the
136 mice with maximal coerced treadmill exercise (Fig. 2a). MM (WT) mice ran farther (Fig. 2b),
137 and attained higher maximal speeds (Fig. 2c) compared to VV littermates. Although oxidative
138 stress and the MM motif were necessary for normal CaMKII activity in stimulated muscle fibres

139 (Fig. 1d and e), the reduced exercise performance in VV mice could be due to muscle extrinsic
140 factors, such as motivation or metabolism. Blood lactate accumulation correlates with perceived
141 effort during progressively intensifying exercise²⁴. However, we found no difference in blood
142 lactate concentration between MM (WT) and VV mice either before or after running (Extended
143 Data Fig. 6a), suggesting that perceived effort was similar. Furthermore, the VV and MM (WT)
144 mice engaged equally in voluntary wheel running (Extended Data Fig. 6b), suggesting that the
145 difference in forced running performance in VV mice was unlikely a consequence of reduced
146 motivation for running. Exercise demands uninterrupted energy supply, and the depletion of
147 blood glucose can be a limiting factor for endurance running in mice²⁵. Furthermore, CaMKII γ
148 promotes hepatic gluconeogenesis²⁶, an important source of blood glucose during exercise²⁷.
149 However, we found no difference in blood glucose between MM (WT) and VV mice before or
150 immediately after running (Extended Data Fig. 6c), suggesting that the MM module does not
151 contribute to blood glucose maintenance under these conditions. In addition, we found no
152 significant difference in the body weight, lean mass, and fat mass between MM (WT) and VV
153 mice; nor did we find a significant difference in their activity inside cages, food intake, oxygen
154 consumption rate (VO₂), CO₂ production rate (VCO₂), respiratory control ratio (RER), or energy
155 expenditure (data not shown) when the mice were monitored individually in the Comprehensive
156 Lab Animal Monitoring System (CLAMS), suggesting that the energy metabolism of MM (WT)
157 and VV mice are similar. Based on these negative findings, we next determined whether the
158 diminished exercise performance observed in VV mice might result from reduced muscle
159 function *in vivo*. We determined the reduction in quadriceps contractility of repeated maximal
160 isometric contractions elicited by direct repetitive electrical stimulation of femoral nerves, in
161 anesthetized mice, as a measure of muscle fatigue (Fig. 2d). This *in vivo* approach allows for the
162 direct examination of muscle function at body temperature, with intact blood flow and
163 neuromuscular communication, while minimizing potential confounding factors derived from
164 circulatory and nervous system feedback²⁸. The VV mice exhibited earlier and enhanced fatigue
165 compared to MM (WT) littermate mice (Fig. 2e and 2f). The reduced performance of the VV
166 mice was unlikely due to developmental defects or gross pathological remodelling, as we found
167 that the VV and MM (WT) mice have similar muscle weight to body weight ratios and grip
168 strength (Extended Data Fig. 7a-g). In addition, the contents of mitochondrial complexes in
169 muscles (Extended Data Fig. 8a), and oxidative phosphorylation and glycolysis capacities of
170 isolated FDB muscle fibres were all similar between MM (WT) and VV mice (Extended Data
171 Fig. 8b and c). Furthermore, we found no significant change in the fatigue-resistant type I fibres,
172 and noted significant but subtle switches among type II fibres in VV quadriceps muscles, which
173 were unlikely to explain the reduced endurance capacity (Extended Data Fig. 9a and b). Taken
174 together, these data support a view that ox-CaMKII enhances dynamic responses to exercise and
175 skeletal muscle performance.

176
177 Intracellular Ca²⁺ grades myofilament interactions, thereby serving as an essential signal for
178 muscle performance, and CaMKII promotes intracellular Ca²⁺ release in excitable tissues,
179 including skeletal muscle^{17,18}. We used a validated *in vitro* model of skeletal muscle fibre
180 fatigue²⁹, under conditions where we monitored the intracellular Ca²⁺ transients (see Methods,
181 Fig. 2g). The VV fibres had reduced Ca²⁺ transients under basal conditions compared to MM
182 (WT) counterparts (Fig. 2h). Fatigue is marked by reduced intracellular Ca²⁺ transients³⁰, and
183 VV fibres showed significantly greater reductions in these Ca²⁺ transients compared to MM
184 (WT) (Fig. 2i). In order to test whether the exaggerated fatigue Ca²⁺ phenotype in VV muscle

185 fibres was a consequence of ROS-signalling, we treated MM (WT) fibres with NAC. The MM
186 fibres exposed to NAC phenocopied the Ca^{2+} release profiles measured in VV fibres (Fig. 2h-j).
187 We next used a genetic approach to reduce ROS by isolating muscle fibres from *Ncf1*^{-/-} mice that
188 lack p47³¹, an essential protein cofactor for NADPH oxidases that are an important source of
189 ROS in skeletal muscles³²⁻³⁴. Similar to NAC treated MM (WT) fibres, the *Ncf1*^{-/-} fibres shared a
190 phenotype of diminished Ca^{2+} transients resembling VV muscle fibres (Fig 2. h-j). Taken
191 together, we interpret these data as supporting a model where ox-CaMKII contributes to
192 enhanced skeletal muscle performance, at least in part, by connecting ROS to mobilization of
193 intracellular Ca^{2+} .

194

195 **Ox-CaMKII regulates acute transcriptional responses to exercise**

196 Exercise imposes metabolic, mechanical and redox stresses on skeletal muscle leading to
197 transcriptional adaptation that is partly orchestrated by CaMKII^{35,36}. We next measured
198 transcriptional responses to submaximal exercise in skeletal muscles, comparing poly(A)⁺
199 transcriptomes by RNA sequencing from MM (WT) and VV littermate mice under identical
200 conditions of speed, time, distance and feeding conditions (Fig. 3a, see Methods). Principal
201 components analysis showed that sedentary MM (WT) and VV muscles had very similar
202 transcriptional profiles (Fig. 3b). In contrast, transcriptional responses to exercise by VV
203 muscles were present, but diminished compared to MM (WT) (Fig. 3b). We found that 582
204 genes were significantly up or down regulated (multiple-test false discovery rate-adjusted *q*-
205 value < 0.05) in the MM (WT) samples, whereas only 216 genes reached the same threshold of *q*
206 < 0.05 in the VV muscles (Fig. 3c and Supplementary table 1). Among the significantly changed
207 genes in VV muscles, most (180, or 83%) were recapitulated by the MM (WT) muscles. To
208 further compare the transcriptional responses of MM (WT) and VV muscles at the level of
209 individual genes, we ranked the exercise-responsive genes identified in the MM (WT) muscles
210 based on their log₂ (fold change) values, as diagrammed (Fig. 3d, left panel), and plotted these
211 genes in heat map palettes (Fig. 3d, middle panel). The changes of the same set of genes in the
212 VV muscles were shown in separate palettes (Fig. 3d, right panel), but in the same order as that
213 of the MM palettes. It is clear that the MM module had heterogeneous effects on the response of
214 individual genes to exercise: most exercise responsive genes preserved their qualitative
215 responses in VV muscles, while the up- or down-regulations of a small number of genes were
216 completely blunted or even reversed. The results suggest that ox-CaMKII plays important, but
217 specified, roles in the acute transcriptional response of skeletal muscles to exercise.

218

219 We next used QIAGEN Ingenuity Pathway Analysis³⁷ to extract biological pathway information
220 from genes that showed a large shift (more than $\pm 2\sigma$) in expression in response to exercise. We
221 found that in the MM (WT) muscles, eight out of the ten most significantly enriched biological
222 function terms were related to inflammation (Fig. 3e). Strikingly, exercise induced lesser
223 changes of the genes involved in the inflammatory response in the VV muscles (Fig. 3e). In
224 contrast, the top 10 most enriched biological functions in VV muscles included terms such as
225 “differentiation of muscle cells” and “growth of muscle tissue”, which were expected for the
226 adaptive response to exercise³⁶. Importantly, the MM (WT) muscles shared a similar pathway
227 enrichment for these biological functions (Fig. 3f). We then directly compared the
228 transcriptomes of exercised MM (WT) and VV muscles to identify a list of genes that showed
229 the most prominent differences (more than $\pm 2\sigma$) between genotypes under this post-exercise
230 condition. When these differentially regulated genes were analysed by Ingenuity Pathway

231 Analysis, the results (Fig. 3g) further supported the prominent difference in inflammatory
232 responses between exercised MM (WT) and VV muscles: exercised MM (WT) muscles showed
233 significant enrichments ($p < 0.05$) and activation (z score ≥ 2.0) of multiple biological functions
234 related to inflammation (Fig. 3g). Our results suggest that ox-CaMKII plays an important role in
235 coupling ROS to the activation of physiological inflammatory response pathways, a well-
236 established adaptive response to a single bout of unaccustomed exercise³⁸. Under disease
237 conditions CaMKII has been shown to promote inflammation in the heart³⁹⁻⁴¹ and airway¹¹, and
238 to function in mast cells¹¹, macrophages⁴²⁻⁴⁵ and T cells⁴⁶. Our data unambiguously established
239 ox-CaMKII as a molecular connection between inflammatory responses and physiological ROS
240 signalling.

241

242 **MM enacted the performance/disease trade-off in flies**

243 For it to be fixed by natural selection, the MM module likely provided fitness benefits to the
244 ancestral vertebrates. Using *Drosophila melanogaster* as a model, we next tested whether the
245 MM module could exert beneficial effects on physiological performance in an invertebrate. We
246 reasoned that if a performance benefit is conferred by the MM module in flies it would suggest
247 that the cellular context of invertebrates was permissive for the physiological benefits of ox-
248 CaMKII. Since climbing involves insect leg muscles that are functionally and physiologically
249 analogous to skeletal muscles of vertebrates⁴⁷, we tested the climbing ability MM and VV (WT)
250 flies. We placed the flies into vertical race-tracks too narrow for flying, but wide enough for
251 climbing. When the flies were dislodged to the bottom of the race-tracks by vertical orientation
252 of the apparatus, they climbed upwards as an innate escape response (Fig. 4a). Strikingly, the
253 MM flies climbed at a significantly higher velocity than VV (WT) flies (Fig. 4b, control
254 condition). The superior climbing performance conferred by the MM module was dependent on
255 the physiological redox state, because ingesting food supplemented with the antioxidant NAC for
256 24 hours dose-dependently reduced the performance of MM but not VV (WT) flies (Fig. 4b,
257 NAC-treated conditions). The MM flies climbed at similar velocities to VV (WT) flies after
258 treatment by NAC (Fig. 4b). These results suggested that the MM module was capable of
259 enhancing physiological responses to ROS in an invertebrate and likely also in ancestral
260 vertebrates. To determine whether the MM module plays a direct role in *Drosophila*
261 *melanogaster* striated muscles, we evaluated the performance of denervated hearts in MM and
262 VV (WT) flies. In *Drosophila* the heart is a muscular tube that is experimentally accessible (Fig
263 4c). The hearts of MM flies had significantly better basal performance evidenced by significantly
264 higher shortening velocity and relaxation rate (Fig. 4d and e). Similar to the vertical climbing
265 assay, the performance benefits of the MM module in heart tubes were lost after exposure to
266 NAC (Fig 4d and e). We interpreted these studies to show that ox-CaMKII was capable of
267 producing ROS-driven physiological enhancements across evolutionarily distant species.

268

269 The striking benefits of MM modules on motor function and cardiac performance in flies (Fig. 4)
270 contrasted with the fact that MM module promoted death when the flies were exposed to lethal
271 doses of paraquat (Fig. 1c). Conceivably, when ROS increase above an optimal level, the MM
272 module transduces the toxic ROS signal into excessive CaMKII activity that is detrimental to the
273 flies. To test this possibility, we examined the effects of a sublethal dose of paraquat (4 mM for
274 24 hours) on climbing (Fig. 5a). After paraquat treatment, the MM flies exhibited significantly
275 reduced climbing velocity, whereas VV (WT) flies were unaffected (Fig. 5a). The notion that
276 excessive CaMKII activity is detrimental to motor function in invertebrates is supported by the

277 observation that a hyperactive mutation of CaMKII impaired motor function of *Caenorhabditis*
278 *elegans*⁴⁸. We further examined the effects of very low dose paraquat feeding (1 mM for 3 to 6
279 days) on spontaneous ambulatory activity. We found that there was no difference in spontaneous
280 ambulation between MM and VV (WT) flies at baseline, whereas exposure to food containing
281 paraquat significantly reduced daily ambulatory activity counts only in MM flies (Fig 5b).
282 Similarly, the benefits of the MM module on performance of denervated hearts were completely
283 abrogated when the fly hearts were exposed to 10 mM paraquat for 90 minutes (Fig 5c and d);
284 and longer exposure (150 minutes) to paraquat disrupted the contraction of significantly higher
285 portions of MM than VV hearts (Fig 5e, and supplementary video 1). Taken together, effects of
286 the MM module in fly CaMKII are strikingly similar to those in mice, strongly supporting the
287 case for a performance/disease trade-off. The MM module promotes motor function in both
288 species in response to physiological ROS, but switches from an asset to a liability when the
289 organisms are challenged by pathological oxidative stress.

290
291 Finally, we tested whether insertion of the MM module in CaMKII could establish unique
292 connections between ROS and gene expression in flies, potentially mirroring the situation in
293 mice (Fig. 3). Many mammalian transcription regulators targeted by CaMKII have orthologous
294 counterparts in *Drosophila melanogaster* (<http://flybase.org/>). We fed our MM and VV (WT)
295 flies with 10 mM paraquat for 24 hours at 25 °C, a regimen that induced elevated mortality in
296 MM flies (Fig. 1c), and is known to induce a stereotyped transcriptional response in *Drosophila*
297 *melanogaster*⁴⁹. We focused on a subset of the paraquat-induced fly genes⁴⁹ whose paralogues
298 in mice were altered by exercise. We randomly selected some of these genes and confirmed by
299 RT-qPCR that all were significantly regulated by paraquat in MM and VV flies (Fig. 5f).
300 Strikingly, none of these genes showed a difference in expression between MM and VV flies
301 consuming control food, while a subset exhibited significant differences between MM and VV
302 flies after paraquat feeding (Fig. 5f). The results suggest that introducing the MM module to fly
303 CaMKII bridges ROS to the expression of a specific set of genes, reminiscent of the
304 transcriptional effects of the MM module in exercising mouse skeletal muscles (Fig. 3).

305 306 **Discussion**

307 Our studies provide new *in vivo* and *in vitro* evidence that ox-CaMKII directly orchestrates
308 connections between ROS, intracellular Ca²⁺ and gene transcription that lead to physiological
309 advantages in mice, and, presumably, other vertebrates. Our pattern-based phylogenetic results
310 indicate this advantage evolved concurrent with the establishment of the modern vertebrate body
311 plan and its highly active behavioural ecology. It seems likely that ox-CaMKII was a key
312 innovation in facilitating the heightened physiological output required of these derived
313 anatomical systems and thus played a key role in the initial establishment and continued
314 evolutionary success of vertebrates. The conservation of the CM/MM module in all isoforms of
315 vertebrate CaMKII further suggests that ox-CaMKII plays diverse physiological roles, beyond
316 those uncovered by this study in the skeletal muscles. The formative evolutionary role of the
317 MM module is paired with considerable irony, given the well-recognized contributions of ox-
318 CaMKII to major chronic and life-threatening human diseases. The striking observation that the
319 MM module enacts the performance/disease trade-off in flies, an invertebrate diverged from our
320 common ancestors for more than 500 million years is particularly worth noting. It suggests that
321 the MM module is a concise but highly impactful ROS sensor, and once it was obtained by
322 CaMKII in the ancestral vertebrate, the MM (CM) module was sufficient to couple ROS to a

323 wide range of CaMKII targets important for enhanced performance, gene expression, disease and
324 death. The totality of this information strongly supports the conclusion that the CM/MM module
325 is an evolutionary trade-off in vertebrates that uses ROS to enhance physiological performance,
326 while simultaneously bestowing sensitivity to ROS for promoting chronic diseases, many of
327 which transpire in older organisms, beyond the reach of natural selection.

328

329 **Acknowledgement**

330 We thank Drs. Hal Dietz and Gregg Semenza for their insightful comments and suggestions,
331 Teresa Ruggle for assistance in graphic design, Benjamin Garlow for assistance in developing
332 KTR, Jinying Yang for managing mice, and Tran Nguyen for maintaining fly stocks.

333

334 This work was supported by the National Institutes of Health (R35-HL140034 to MEA, R37-
335 AR055099 to EOH and MFS, R01-AR059179 and R21-AR067872-01 to RML, R01-HL124091
336 to MCV and AC, R01-NS079584 to MNW) and a MOST grant (MOST-107-2636-B-002 -001 to
337 MEA).

338

339 **Author contributions**

340 Q.W., G.S.B. and M.E.A. contributed to the conception and design of the work; Q.W., E.O.H.,
341 M.C.V., I.D.B., J.M.G., K.R.M., A.W., S.A., N.L., D.M., K.R.W. and R.M.L. contributed to the
342 acquisition of the data; Q.W., E.O.H., M.C.V., I.D.B., K.R.M., A.W., S.A., C.M.A., L.D.F.,
343 C.C.T., D.M., S.R., M.N.W., A.C. and M.S.F. analysed and interpreted the data; Q.W., G.S.B.
344 and M.E.A drafted the manuscript; Q.W., G.S.B. and M.E.A. substantively revised the
345 manuscript.

346


347 **Data availability statement**

348 Raw sequencing data and the gene-expression matrix are available in the Gene Expression
349 Omnibus (GEO) under accession number GSE132520. All other data are available from the
350 corresponding author upon reasonable request.

351

352
353


Figure 1



354
355

356 **Fig. 1 | The MM motif in CaMKII arose in vertebrates, allowing CaMKII activation by**
357 **ROS. a, CaMKII activation is initiated by binding Ca²⁺/CaM, but Ca²⁺/CaM independent**
358 **CaMKII activity is sustained by post-translational (PTM) modifications of the regulatory**

359 domain. The CaMKII regulatory domain sequences of *Drosophila melanogaster* CaMKII and
360 *Mus musculus* CaMKII γ are shown. **b**, Phylogenetic origin and conservation of key residues for
361 the activating PTMs of CaMKII (divergence time estimates from Kumar et al⁵⁰). mya: million
362 years ago; bya: billion years ago. **c**, Replacing the VV residues of *Drosophila melanogaster*
363 CaMKII with MM increased mortality caused by exposure to 25 mM and 50 mM paraquat (PQ)
364 incorporated in 5% sucrose solution at room temperature (21 °C, left panel) after 24 hours (24-h)
365 and 48 hours (48-h), and by exposure to 10 mM paraquat at 25 °C after 24 hours (right panel).
366 Only one out of 1020 flies fed control food (5% sucrose solution) died (not shown). *P*-values
367 from Fisher's exact test are shown above the square brackets. N = 216 and 217 respectively for
368 MM and VV flies treated at the room temperature; n = 510 for both genotypes of flies treated by
369 either control or paraquat solutions under the 25 °C test condition. **d**, Representative confocal
370 micrographs of MM and VV mouse FDB muscle fibres expressing CaMKII-KTR before and
371 after field electrical stimulation in the absence or presence of 2 mM N-acetylcysteine (NAC).
372 Arrows indicate nuclei. **e**, Quantification of CaMKII activity (cytosolic to nuclear CaMKII-KTR
373 signal ratio) in MM and VV fibres before and after field stimulation in the absence or presence
374 of 2 mM NAC (Two-way ANOVA followed by Sidak's multiple comparisons test. n = 14 nuclei
375 from 6 fibres (MM) and n = 21 nuclei from 7 fibres (VV) in the left panel, and n = 11 nuclei
376 from 5 fibres (MM) and n = 16 nuclei from 6 fibres (VV) in the right panel. *P*-values are shown
377 above the brackets).
378




379
380
381
382
383
384
385

Fig. 2 | Ox-CaMKII supports exercise performance and enhances Ca^{2+} transients in mouse skeletal muscle fibres. **a**, Protocol for treadmill exercise. **b**, Running distance, and **c**, maximal speed attained prior to exhaustion. Unpaired Student's *t* test, two-tailed, *P*-value shown above the square brackets, *n* = 20 MM (WT) mice and *n* = 27 VV mice. **d**, Experimental apparatus and electrical stimulation protocol for assessing quadriceps muscle performance *in vivo*. **e**, Averaged

386 traces of quadriceps torque (normalized against maximum) from MM and VV mice during
387 optimized nerve stimulation, n = 10 VV mice, and n = 11 MM mice. **f**, Quantification of fatigue
388 defined by torque reduction divided by initial torque of each individual mouse, as shown in e.
389 Unpaired Student's *t* test, two-tailed, *P*-value shown above the square bracket. **g**, Protocol for
390 field electrical stimulation of isolated FDB muscle fibres loaded with the Ca²⁺ sensitive
391 fluorescent dye Rhod2. Rhod2 fluorescence during one cycle of electrical stimulation in MM and
392 VV fibres, an MM fibre treated by NAC, and a *Ncf1*^{-/-} fibre, before (h) and after (i) fatigue. **j**,
393 Quantification of peak Ca²⁺ transients as measured in h and i. Before fatigue: n = 42 MM, n = 27
394 VV, n = 8 MM + NAC, and n = 32 *Ncf1*^{-/-} fibres; after fatigue: n = 40 MM, n = 27 VV, n = 8
395 MM + NAC, and n = 32 *Ncf1*^{-/-} fibres; *P*-values are shown above the brackets; Dunnett's
396 multiple comparisons tests comparing all other groups to VV fibres. Horizontal lines in b, c, f,
397 and j indicate medians.
398

399

Figure 3



400

401 **Fig. 3 | Ox-CaMKII is important for acute transcriptional responses to exercise.** a, Protocol

402 for submaximal exercise and muscle collection. b, Principal components analysis (PCA) of

403 RNA sequencing results of sedentary (sed) and exercised (ex) muscle samples. The distance

404 between samples in PCA corresponds to similarity (near) or difference (far) in their

405 transcriptional profiles (n = 4 mice for each group). c, Numbers and overlap of significantly

406 changed (false discovery rate-adjusted q -value < 0.05) genes in response to exercise in MM and
407 VV muscles. Arrows indicates up- (\uparrow) or down-regulation (\downarrow) when comparing exercised
408 muscles to sedentary muscles. Left panel of **d**, diagram of the layouts for arranging genes in the
409 middle and right panels; middle panel of **d**, genes whose expression was significantly ($q < 0.05$)
410 changed in response to exercise in the MM (WT) muscles are ordered according to the diagram
411 in the left panel, and their \log_2 (fold changes) are represented by colour; right panel, the \log_2
412 (fold change) of the same genes in response to exercise in the VV muscles are shown. **e**, Top-10
413 most significantly (smallest P -values) changed functions identified by Ingenuity Pathway
414 Analysis comparing transcriptomes of exercised MM muscles to their sedentary counterparts.
415 Corresponding enrichment P -values of the same functions in the exercised VV muscles are
416 plotted for comparison. **f**, Top-10 most significantly (smallest P -values) changed functions
417 identified by Ingenuity Pathway Analysis comparing transcriptomes of exercised VV muscles to
418 their sedentary counterparts. Corresponding enrichment P -values of the same functions in the
419 exercised MM muscles are plotted for comparison. **g**, Ingenuity pathway analysis directly
420 comparing transcriptomes of exercised MM and VV muscles. In (e-g), activation, depression or
421 bidirectional changes of the biological functions are determined by the z -score of Ingenuity
422 Pathway Analysis for each pathway ($z \geq 2.0$ for activation, $z \leq -2.0$ for depression, otherwise for
423 bidirectional changes).
424

425




Figure 4


426

427

428 **Fig. 4 | MM module couples ROS to improved performance in *Drosophila melanogaster*.** **a**,
 429 Diagram for climbing test. **b**, Vertical climbing velocity of flies treated by control food (5%
 430 sucrose) or food containing 10 mM or 50 mM NAC for 24 hours; n = 93 control-treated MM, n =
 431 90 10 mM NAC-treated MM, n = 86 50 mM NAC-treated MM, n = 94 control-treated VV, n =
 432 91 10 mM NAC-treated VV, n = 94 50 mM NAC-treated VV. Horizontal lines indicate
 433 medians. *P*-values shown above the brackets, Tukey's multiple comparisons test. **c**, diagram of a
 434 fly heart (in blue color). **d** and **e**, Cardiac performance indices of MM and VV hearts before and
 435 after 60-minute treatment by 10 mM NAC. The shortening velocity (**d**) and relaxation rate
 436 were assessed. n = 27 MM hearts per condition and n = 29 VV hearts per condition. Horizontal
 437 lines indicate medians. *P*-values shown about the brackets in (**d**) and (**e**), Tukey's multiple
 438 comparisons test.
 439

440
441

Figure 5




442
443

444 **Fig. 5 | MM module sensitizes flies to pathological oxidative stress.** **a**, Vertical climbing
445 velocity of flies treated by control food or food containing 4 mM paraquat for 24 hours at 25 °C;
446 n = 68 control-treated MM, n = 74 paraquat-treated MM, n = 57 control-treated VV, n = 75
447 paraquat-treated VV flies. Horizontal lines indicate medians. *P*-value from Sidak's multiple
448 comparisons test shown in the graph. **b**, Daily activity counts of MM and VV flies consuming a

449 control or paraquat (1mM) diet. Diets started at day 1 and behaviour monitoring occurred
450 between days 3 and 6 (Points and error bars are mean \pm SEM. *P*-values calculated using Tukey's
451 multiple comparisons test for effect of paraquat, n = 29 control MM, n = 21 paraquat-treated
452 MM, n = 31 control VV, and n = 21 paraquat-treated VV flies). **c and d**, Cardiac performance of
453 hearts bathed first in control artificial haemolymph and then in haemolymph containing 10 mM
454 of paraquat for 90 minutes. n = 26 hearts per genotype and the *P*-values from Tukey's multiple
455 comparisons test are shown. Horizontal lines indicate medians. **e**, All MM and VV hearts
456 showed normal contraction before paraquat treatment, however, after exposure to 10 mM
457 paraquat for 150 minutes, significantly more MM hearts became hypokinetic, severely
458 hypokinetic or akinetic (examples of categorical cardiac performance are in the supplementary
459 video 1). n = 26 hearts per genotype, *P*-value from Chi-square test. **f**, expression heat map of a
460 subset of paraquat responsive genes that was quantified by RT-qPCR after RNA was extracted
461 from flies ingesting control food (Control, 5% sucrose solution) or paraquat (10 mM of paraquat
462 in 5% sucrose solution) for 24 hours at 25 °C (n = 8 biological replicates per group, each
463 containing 15 males and 15 females). All of these genes were significantly upregulated by
464 paraquat (*P* < 0.05, not shown, two-Way ANOVA). No genes showed significant differences
465 between MM and VV flies fed control food, whereas a subset of genes had significantly higher
466 expression in MM than in VV flies after exposure to paraquat (*P*-values shown in the table.
467 Sidak's multiple comparisons test).
468

Extended Data Fig. 2




478
479

480 **Extended Data Fig. 2 | Generation of *CaMKII^{MM}/CaMKII^{MM}* flies using CRISPR.** **a**,
481 Schematics of the CRISPR guide designs and the single strand template (ssODN-1R) that
482 mediated the homology directed recombination, resulting in mutations of codons from encoding
483 VV to encoding MM, and introduction of the silent mutations for NsiI/NsiI-HF restriction site.
484 Primers-F1/R2 anneal outside of the range homologous to the ssODN-1R to amplify the genomic
485 region for genotyping. **b**, Chromatograms of sequencing results from the PCR products amplified
486 by primers F1 and R2 from homozygous VV/VV (top) and MM/MM (bottom) flies. The VV/VV
487 (wild type) and MM/MM flies are referred to as VV and MM flies in the text for brevity. **c**,
488 Agarose gel electrophoresis of PCR products from flies backcrossed into the w1118 or iso31
489 genetic background for 5 generations. The genotypes of flies were determined by digesting the
490 493 bp PCR products with the restriction enzyme NsiI. PCR products amplified from the VV
491 allele were resistant to NsiI, while those from the MM allele were cut into 345 bp and 148 bp
492 fragments.
493

494

Extended Data Fig. 3



495

496

497 **Extended Data Fig. 3 | Design and validation of the CaMKII activity reporter, CaMKII-**

498 **KTR.** **a**, Schematic of the CaMKII kinase activity translocation reporter CaMKII-KTR

499 (abbreviated as KTR). The N-terminus of the KTR is a well-characterized CaMKII-interacting

500 domain from HDAC4 (AA582-624⁵¹), followed by a nuclear localization signal (NLS) and a


501 nuclear exporting signal (NES). The high affinity CaMKII substrate consensus sequence

502 (LXRXXSV) was built into both the NLS and NES (see Method). The C-terminus of the


503 CaMKII-KTR is an enhanced green fluorescent protein (EGFP). **b**, The KTR shuttles between
504 the nucleus and cytosol. Phosphorylation by CaMKII decreases the strength of the NLS while
505 increases the strength of the NES, resulting in a net translocation of the KTR into the cytosol.
506 The ratio between the cytosolic and nuclear signals of the KTR corresponds to the overall
507 activity of CaMKII inside the cells. **c**, Fluorescent images of KTR transfected into RPE-1 cells
508 alone, co-transfected with CaMKII, with kinase-dead CaMKII^{K43M}, or with a CaMKII-specific
509 inhibitor CaMKIIN. The arrowheads indicate nuclei. Cells were imaged at time -60 seconds (s),
510 0, 60 s, and 120 s, and were treated at time 0 with 50 μ M of histamine. Treatment with vehicle
511 (medium) did not elicit a response and is not shown. **d**, Quantification of cytosolic to nuclear
512 KTR signal ratios in RPE-1 cells as exemplified in **c** immediately before and 60 seconds after the
513 histamine treatment. *P*-values are shown in the graph, Sidak's multiple comparisons test for
514 repeated measurement comparing before and after histamine treatment. **e**, Changes in KTR
515 cytosolic to nuclear signal ratios 60 s after histamine treatment compared to time 0 in cells
516 shown in **d**. Horizontal lines indicate the means. *P*-values are shown in the graph, Dunnett's
517 multiple comparisons test. In (d) and (e), *n* = 36 KTR transfected cells, *n* = 19 KTR + CaMKII
518 cells, *n* = 30 KTR + CaMKII^{K43M} cells, and *n* = 30 KTR + CaMKIIN cells. Data in (d) and (e)
519 were from at least 2 independent experiments.
520
521

Extended Data Fig. 4

a



b




522
523

524 **Extended Data Fig. 4 | Generation of knock-in *CaMKII^{VV}/CaMKII^{VV}* mice.** **a**, Schematics of
525 the *CaMK2g* endogenous locus (top), targeting vector (middle), and targeted locus (bottom).
526 The MM residues are encoded by exon 10. The gene targeting was carried out on ES cells of
527 C57BL6/n background. **b**, chimeric mice bearing the targeted VV allele were crossed with Cre
528 mice to remove the Neo-pGK cassette between the two LoxP sites. The resulting
529 *CaMKII^{MM}/CaMKII^{VV}* heterozygous mice were generated backcrossed to C57BL/6J mice for >7
530 generations.
531

532

Extended Data Fig. 5




533

534

535 **Extended Data Fig. 5 | Expression of CaMKII isoforms in representative striated muscles**
536 **quantified by RT-qPCR. a**, Expression of CaMKII isoforms in the heart, soleus, TA (tibialis
537 anterior), and EDL (extensor digitorum longus) muscles relative to *Gapdh*. Each tissue was
538 represented by three individual wild type animals. **b**, RT-qPCR assay for the expression of
539 *Camk2g* in gastrocnemius muscles from MM and VV mice; n = 5 for each genotype. In a and b,
540 horizontal lines indicate means.
541

542

Extended Data Fig. 6



543


544

545 **Extended Data Fig. 6 |Blood lactate, glucose, and voluntary running.** a, Lactate
546 concentrations measured with a drop of blood from tail tips before and immediately after
547 treadmill exercise, $n = 14$ MM and $n = 20$ VV mice, no statistically significant differences were
548 present between genotypes either before or after exercise. b, Counts of wheel rotations during
549 24 hours on the 6th day of running wheel access by individual MM ($n = 11$) and VV ($n = 11$)
550 mice, no statistically significant difference was found between genotypes. c, Blood glucose
551 concentration measured from the same mice at the same time as in (a). In a-c, horizontal lines
552 indicate the medians.

553

554

Extended Data Fig. 7



555

556

557

558

559


560

561

Extended Data Fig. 7 | MM (WT) and VV skeletal muscles show no difference in weight and strength. a-f, Muscle to body weight ratios of representative skeletal muscles, a, EDL (extensor digitorum longus). b, Soleus. c, TA (tibialis anterior). d, Gastrocnemius. e, Triceps. f, Quadriceps. g, Grip force of front paws. Horizontal bars indicate means, n = 5 MM and n = 5 VV mice from (a-g).

562
563

Extended Data Fig. 8




564
565

566 **Extended Data Fig. 8 | Oxidative and glycolytic capacities of MM and VV muscles are**
567 **similar.** **a**, Western blot of gastrocnemius muscle extracts showed no difference in the
568 expression of representative protein subunits from mitochondrial oxidative phosphorylation
569 complexes (n = 5 mice for each genotype). Isolated flexor digitorum brevis (FDB) fibres were
570 analysed for **(b)** oxygen consumption (OCR) and **(c)** extracellular acidification (ECAR) rates.
571 Points and error bars are mean \pm SEM. No statistically significant (multiple t-test adjusted for
572 false-discovery) differences were found between MM and VV fibres, n = 5 MM (WT) mice and
573 n = 4 VV mice in b and c.
574

575

Extended Data Fig. 9



576

577

578

579

580

581

582

583

584

585

586

587

Extended Data Fig. 9 | Analysis of skeletal muscle fibre types in MM and VV mice. **a**, an example cross sectional image of quadriceps muscle with immunostaining for myosin heavy chain isoforms I (blue), IIA (green), IIB (red), and IID (black, unstained). Note that this image was chosen to show the staining of all four types of myosin heavy chain isoforms, and the proportions of isoforms in this image do not reflect the entire cross section of the muscle because fibre types are not uniformly distributed throughout the cross-section of the muscles. **b**, quantification of the percentages of fibre types determined by myosin heavy chain isoform expression in MM (n = 5 mice, 1 section per mouse, 20110 fibres counted in total) and VV (n = 5 mice, 1 section per mouse, 22922 fibres counted in total) mice (Fisher's exact test comparing the same fibre types between MM and VV muscles).

588 **Methods**

589

590 **Animal use**

591 All animal handling procedures were in accordance with National Institutes of Health guidelines
592 and were approved by the Institutional Animal Care and Use Committees of Johns Hopkins
593 University School of Medicine.

594

595 **Generation of *CaMKII^{MM}* point mutation in *Drosophila melanogaster* by CRISPR mediated 596 gene editing**

597 The genomic sequence of the *Drosophila melanogaster CaMKII* gene was used in the CRISPR
598 guide design tool (<http://crispr.mit.edu/>) to create the CRISPR guides. The guide #1
599 (GTTACAGCAACGCGAACGTG) was chosen due to its close proximity to the codons
600 encoding V281 and V282 and its lack of high probability off-targets. The guide #1 was ordered
601 as complementary oligomeric DNA (Integrated DNA Technologies) and cloned into the pU6-
602 BbsI-ChiRNA plasmid⁴⁶ [the pU6-BbsI-chiRNA was a gift from Melissa Harrison & Kate
603 O'Connor-Giles & Jill Wildonger (Addgene plasmid # 45946 ; <http://n2t.net/addgene:45946> ;
604 RRID:Addgene_45946)]. A single strand 176nt ultramer DNA oligo (ssODN-1R) was designed
605 as the template for HDR-mediated point mutations and was ordered from Integrated DNA
606 Technologies (Extended data Fig. 2a). The sequence of ssODN-1R is
607 “AACATTGTCGTAAGTATGGCTCCCTTTAGCTTGCGCCGCGCATTAAATTTCTTGAGA
608 CAGTCTACGGTTTCTTGGCGATGCATCATGGAAGCGACTCGTTCGCGTTGCTGTAAC
609 AATGTTTTTTCATTATCTTTATGTAAACCTAAGAGAAAAATTAGTCTGCACTTACACA
610 AATC”. Injection of the ssODN-1R and the guide RNA encoding plasmids into fly embryos was
611 carried out by Rainbow Transgenic Flies, Inc (3251 Corte Malpaso Unit 506 Camarillo CA).
612 Genotyping was carried out by PCR amplification from genomic DNA, extracted from the wings
613 of the flies, with primer-F (GTCGGTTATCCACCCTTTTG), and primer-R
614 (GACGCCAAGTATATTGATGTGG) followed by Sanger sequencing and NsiI/NsiI-HF
615 digestion. The flies with the correct *CaMKII^{MM}* allele were backcrossed with iso31 flies⁵² for five
616 generations to minimize the possibility of carrying off-targets from the CRISPR-mediated gene
617 editing.

618

619 **Phylogenetic survey of CaMKII**

620 Most CaMKII orthologues listed in Supplementary Fig. 1 were identified in the Interpro database
621 (<http://www.ebi.ac.uk/interpro/entry/IPR013543/taxonomy>), based on the criteria that the sequences
622 have the conserved CaMKII association domain, and a kinase domain. Additional sequences
623 were uncovered by BLAST in the NCBL nucleotide database and translated into proteins
624 (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>). The CaMKII sequences were aligned using the
625 Molecular Evolutionary Genetics Analysis software MEGA-X⁵³
626 (<https://www.megasoftware.net/>). The evolution of an oxidation-sensitive amino acid pair at loci
627 281/282 of the CaMKII regulatory domain is an unambiguous synapomorphy of crown-clade
628 vertebrates among Deuterostomata. The initial identity of this pair was CM, with the 281
629 cysteine likely being subsequently replaced by a methionine in one of the two paralogs that
630 resulted from a full round of genome duplication that occurred prior to the origin of the
631 vertebrate crown clade. Our phylogenetic survey did recover a small number of non-
632 deuterostome taxa that also exhibit oxidizable residues at those same regulatory loci. The large
633 phylogenetic separation between these taxa, both individually and collectively, from

634 Deuterostomata leaves it clear that they evolved independent of the vertebrate condition; they are
635 also MM rather than the CM of the earliest vertebrates. As a greater taxonomic diversity of
636 metazoan genomes become available, a meaningful probabilistic analysis of ox-CaMKII
637 evolution outside of Deuterostomata will be possible. But that analysis is highly unlikely to
638 question the evolutionarily unique nature of vertebrate ox-CaMKII.

639

640 **Generation of *CaMKII^{VV}* knock-in mutation in mice**

641 *CaMKII^{VV}* knock-in mice were generated by GenOway (<https://www.genoway.com/>) with mouse
642 embryonic stem cells of the C57BL/6 background as specified in Extended Data Fig. 4. The mice
643 used in experiments had been further backcrossed to C57BL/6J mice (The Jackson Laboratory,
644 000664) and all experiments were carried out with littermates.

645

646 **Western blotting for mitochondrial complexes**

647 Protein extracts were prepared from frozen tissue with T-PER Tissue Protein Extraction Reagent
648 (Thermo Scientific, #78510) in the presence of protease (Sigma-Aldrich, P8340) and
649 phosphatase (Sigma-Aldrich, P0044) inhibitors. The primary antibodies were the Total OXPHOS
650 Rodent WB Antibody Cocktail from Abcam (ab110413), and GAPDH (D16H11) XP® Rabbit
651 mAb (Cell Signalling, #5174). Data were collected by LI-COR Odyssey Fc (Lincoln, Nebraska
652 68504 USA).

653

654 **Skeletal muscle fibre typing**

655 Skeletal muscle fibre composition was determined by immunostaining following a standard
656 method⁵⁴. The primary antibodies BA-F8-c (myosin heavy chain, slow), SC-71-c (Myosin Heavy
657 Chain Type IIA), BF-F3-c (Myosin Heavy Chain Type IIB), 6H1-s (myosin heavy chain, fast,
658 IIX) were obtained from Developmental Studies Hybridoma Bank (University of Iowa).

659

660 **Paraquat treatment and behaviour study of flies**

661 To determine the effects of paraquat on mortality, newly eclosed flies were sorted under CO₂
662 anesthetization and placed into individual vials, and each vial received 10 males and 10 females.
663 When the flies reached 5 to 7 days old, they were transferred into vials containing a filter paper
664 pad (cut from Bio-Rad #1704085) soaked with 600 µL of 5% sucrose solution (control) or 5%
665 sucrose solutions containing 10 mM, 25 mM or 50 mM paraquat (Sigma-Aldrich, # 856177).
666 Mortality of flies was recorded at 24 and 48 hours after initiation of the treatment.

667

668 To test the negative geotaxis (climbing), females were collected and aged, as above, and kept in
669 vials in groups of 10 flies. For low dose paraquat treatment, the flies were treated by 5% sucrose
670 or 5% sucrose + 4 mM paraquat for 24 hours at 25 °C. They were then transferred into vertical
671 test tracks made from 25 mL serological pipette tubes. During the climbing test, the flies were
672 dislodged to the bottom of the tubes by rapidly tapping the vials on the desktop for 10 times and
673 climbing was video recorded for subsequent analysis. Each group of flies was tested for 10
674 consecutive trials at 30 seconds intervals. The vertical distances the flies climbed in 6 seconds
675 since the last tap (time 0) were used to calculate the vertical velocity of climbing. Flies that
676 initiated flight or paused during the 6-second time window were excluded from the analysis. We
677 found that the flies performed reproducibly from the second to tenth trials and presented data
678 from trial 2 in Fig. 4b and Fig. 5a.

679

680 To determine the effects of very low dose paraquat (1 mM) on daily ambulatory activity,
681 individual 1-week old female flies were anesthetized by CO₂ and loaded into tubes containing
682 control or paraquat-containing food and monitored by *Drosophila* Activity Monitoring System
683 (Trikinetics). Fly behaviour was recorded from day 3 to day 6.

684

685 ***Drosophila* cardiac physiological analysis**

686 Dorsal cardiac tubes of ten-day-old female *CaMKII*^{WT} (denoted VV (WT)) and *CaMKII*^{MM}
687 (denoted MM) flies were dissected in oxygenated artificial hemolymph⁵⁵. Myogenic contractions
688 of cardiac tissue were recorded using the Hamamatsu Orca Flash 2.8 CMOS camera on a Leica
689 DM5000B TL microscope with a 10x immersion lens at ~120 frames per second at baseline and
690 after 90 and 150 minutes following the addition of 10 mM paraquat, or 60 minutes after the
691 addition of 10 mM NAC. Cardiac physiological indices were determined using the semi-
692 automated optical heartbeat analysis program^{56,57}. Significant differences between genotypes
693 before and after paraquat treatment for 90 minutes were determined by two-tailed Mann-Whitney
694 tests. After 150 minutes in paraquat, many of the MM hearts no longer contracted and the cardiac
695 indices could not be meaningfully derived. We, therefore, categorized the contractions as normal,
696 hypokinetic (part of the heart contracting), severe hypokinetic (only twitching could be observed
697 in part of the heart), and akinetic (no movement). Representative videos for each category are
698 shown in supplementary video 1. The categorical data were assessed using a Chi-square test.

699

700 **Construction and validation of a CaMKII activity sensor CaMKII-KTR**

701 The CaMKII-KTR was constructed based on the principles previously published¹⁹ and described
702 in the Extended Data Fig. 3. Specifically, the sensor consists (from N-terminus to C-terminus) of
703 a CaMKII-binding region derived from HDAC4, a linker, a nuclear localization signal (NLS), a
704 nuclear exporting signal (NES) and a fluorescent protein. Optimized CaMKII phosphorylation
705 sites were built into the NLS and NES while keeping the NLS and NES functional. The protein
706 sequence of the CaMKII-KTR, excluding the enhanced green fluorescent protein, is
707 EQELLFRQQALLLEQQRIHQRLRNYQASMEAAGIPVSFGSHRPLKRTASVNEDEAPSKKPL
708 ARTASVSSRLRLTLQSS. A cDNA encoding this sequence was ordered as a codon-optimized
709 gene block (gBlock_HDAC4-NLS-NES) from Integrated DNA Technologies
710 (gccaccatgGAACAGGAAGTCTCTTCCGGCAACAGGCACTTCTGTTGGAGCAGCAACG
711 AATCCATCAACTTAGAACTACCAAGCATCAATGGAAGCAGCCGGGATTCCTGTCTC
712 CTTCGGATCTCACAGACCTCTCAAAGGACAGCTAGTGTAACGAGGACGAAGCAC
713 CTTCAAAGAAACCCTTGGCTAGGACCGCTAGTGTCAGTAGTCGACTGGAGCGGTTGA
714 CACTTCAAAGTTCC). The gBlock_HDAC4-NLS-NES was cloned into Cerulean-N1 vector⁵⁸
715 (Cerulean-N1 was a gift from Michael Davidson & Dave Piston, Addgene plasmid # 54742 ;
716 <http://n2t.net/addgene:54742> ; RRID:Addgene_54742) by In-fusion cloning technology (In-
717 Fusion® HD Cloning Plus CE, Takara, CA). The Cerulean encoding region was then replaced by
718 a stretch of cDNA encoding eGFP, derived from pEGFP-C1 (Takara, CA).

719 To validate the response of the CaMKII-KTR to intracellular activity of CaMKII, we transfected
720 (FuGENE® HD Transfection Reagent, Promega, WI) the CaMKII-KTR or co-transfected it with
721 CaMKII, CaMKII^{K43M}, and CaMKIIN constructs into RPE-1 cells and stimulated the cells with
722 50 μM histamine. Before cells were imaged, we replaced the culture medium with Live Cell
723 Imaging Solution supplemented with 4.5 g/L glucose (ThermoFisher Scientific, A14291DJ), and
724 stained their nuclei with Hoechst 33342 (ThermoFisher Scientific, #62249) for 20 minutes to
725 facilitate identification of the nuclei. Fluorescent images were collected using an Olympus IX83

726 epifluorescence microscope equipped with an ORCA Flash 4.0 sCMOS camera and
727 UPLSAPO20X NA0.75 objective lens. Cells were maintained at 37°C in an OkoLabs stage top
728 incubator. Image analyses were carried out in CellProfiler⁵⁹, which identified the nuclei and five-
729 pixel-wide cytosolic rings surrounding the nuclei. The cytosolic to nuclear KTR signal ratios
730 were calculated using the median intensities measured from the nuclei and cytosolic rings of
731 individual cells.

732

733 **Mouse treadmill exercise**

734 Exercise capacity tests were carried out with the Exer 3/6 Rodent treadmill (Columbus
735 Instrument, Columbus, OH). Prior to exercise capacity testing, the mice (12 to 15-week-old)
736 were acclimated to the treadmill for three sessions on three consecutive days. The treadmill was
737 set to 10° inclination and the speed was set to 0, 5, and 10 m/min for the first, second and third
738 acclimation sessions respectively. The electric shock grid at the rear end of the treadmill was
739 turned on and set at stimulation intensity of 9 and frequency of 3 Hz. During exercise capacity
740 testing, each mouse was placed into a lane of the treadmill. The genotype of the animals was
741 blinded to the operator. The exercise protocol consisted of the following steps: (1) 10 m/min for
742 2 minutes for warm up, (2) continuous acceleration from 15 m/min at a rate of 0.6 m/min² until
743 the mouse was exhausted. Exhaustion was determined when the mouse stayed on the shock grid
744 continuously for 5 seconds and was determined by the same observer for all experiments.
745 Glucose and lactate were measured from a drop of blood from the tail tip before and immediately
746 after exercise, using an OneTouch Ultra 2 glucometer (Lifescan, Inc) and a Lactate Plus lactate
747 meter (Nova Biomedical) respectively.

748

749 **Mouse voluntary wheel running, and accompanying metabolic data**

750 Voluntary wheel running data were collected from mice tested for 6 days in an open-circuit
751 indirect calorimeter outfitted with running wheels (Comprehensive Lab Animal Monitoring
752 System, Columbus Instruments) at the Center for Metabolism and Obesity Research service core.
753 Data were collected continuously (Oxymax software, v.5.9, Columbus Instruments). Days 1-5 of
754 acclimation to wheel running were monitored for expected daily increases in number of wheel
755 rotations; the analysis of day 6 is presented. The instrument also provided data for voluntary
756 physical activity in the main cage as indexed by counts of infrared beam breaks, intakes of
757 powdered diet (2018, Envigo), as well as rates of O₂ consumption (VO₂, ml/kg/hr) and CO₂
758 production (VCO₂, ml/kg/hr). Oxymax software calculated the respiratory exchange ratio (RER
759 = VCO₂/VO₂) to assess the oxidized fuel mixture being oxidized, and the rates of energy
760 expenditure (EE, kcal/kg/hr; EE= VO₂ × [3.815 + (1.232 × RER)]). The standard outputs of
761 indirect calorimetry data as per-kg/hr were also renormalized and analysed as per-kg-lean-
762 mass/hr. Body composition data for lean mass and fat mass were obtained using an EchoMRI-
763 100 at the Johns Hopkins University Phenotyping service core. None of the measures from these
764 experiments showed group differences; data from voluntary wheel running are presented.

765

766 **Assessments muscle function *in vivo***

767 Grip strength measurements were carried out as described previously using a grip strength meter
768 (Columbus Instruments, Columbus, OH, USA)⁶⁰. Each mouse performed grip strength test until
769 6 successful attempts were accumulated, and the maximal force among the six attempts was
770 taken as the grip strength.

771

772 *In vivo* quadriceps torque measurement was described previously²⁸. Briefly, the mice were
773 anesthetized under 4% isoflurane and then maintained at 1%. Then their pelvis, torso and femur
774 were stabilized on the apparatus. Afterwards, the distal leg was taped to a lever arm, which was
775 connected with a torque cell. The femoral nerve was stimulated subcutaneously to induce
776 maximal quadriceps muscle contractions and the torque produced was recorded by a connected
777 computer for subsequent analysis. The voltage of the stimulation was optimized prior to the
778 studies to produce the maximal torque.

779

780 ***In cellulo* study of skeletal muscle fibres**

781 Electroporation of DNA into flexor digitorum brevis (FDB) skeletal muscles of mice, muscle
782 fibre culture, measurements of cytosol/nucleus distribution of CaMKII-KTR, and action
783 potential-induced Ca²⁺ transient imaging followed our previous reports^{23,29}. For N-acetyl-L-
784 cysteine (NAC) treatment, the fibres were incubated for 20 minutes with 2 mM NAC (Sigma-
785 Aldrich, St. Louis, MO; catalogue # A-7250). Fibres for study were randomly chosen, and where
786 noted, 2-3 nuclei from the same fibre were studied.

787

788 For Seahorse study, FDB skeletal muscle fibers were isolated one day before the experiments
789 and plated to a laminin-pretreated Seahorse XF96 Cell Culture Microplates overnight. Cell
790 metabolism and bioenergetic analyses of muscle fibers were performed using an Agilent XF96
791 Extracellular Flux Analyzer. XF Cell Mitochondrial Stress Test kit and Glycolysis Stress Test kit
792 were used to measure mitochondria respiration capacities and cellular glycolysis capacities
793 following the manufacturer's protocol. In the mitochondrial stress assay, muscle fibers were
794 incubated in the muscle fiber assay medium (120 mM NaCl, 3.5 mM KCl, 1.3 mM CaCl₂, 0.4
795 mM KH₂PO₄, 1 mM MgCl₂, 5 mM HEPES, and 10 mM glucose, pH 7.4) followed by port
796 injections of final concentration of 1 μM oligomycin, 0.5 μM FCCP, 10 mM pyruvate and 0.5
797 μM antimycin A/rotenone. In the glycolysis stress assay, glucose was not included in the initial
798 muscle fiber assay medium, and then 2 mM glutamine, 10mM glucose, 1μM oligomycin, and
799 50mM 2-DG were injected sequentially. The oxygen consumption rate (OCR) and extracellular
800 acidification rate (ECAR) were analyzed using Seahorse Wave software. OCR and ECAR were
801 normalized by the number of skeletal muscle fibers per well.

802

803 **Mouse treatment and sample collection for RNA sequencing**

804 Male mice between 13 and 15 weeks of age were used for the RNA sequencing experiments. The
805 mice were first acclimated to the treadmill (Exer 3/6, Columbus Instrument, Columbus, OH) for
806 10 minutes on three consecutive days. The treadmill inclined at 10° and the speed was 0, 5
807 m·min⁻¹, and 10 m·min⁻¹ for day 1, 2 and 3 respectively. To minimize the effects of training on
808 the skeletal muscles, the mice rested for 7 days before sample collection. On the day of sample
809 collection, food was withdrawn from the mice at 9:00 AM to minimize the effects of food intake
810 on signalling and gene transcription in the muscles. At 12:00 PM, the mice ran on a treadmill set
811 to 10° of inclination. The treadmill speed was set at 10 m/min for 2 minutes to allow the mice to
812 warm up. The speed was then increased to 15 m/min and then continuously ramped up from 15
813 m/min to 23 m/min at a rate of acceleration of 0.6 m·min⁻². When the running protocol ended,
814 the mice had run 350 meters, which was lower than the average running capacity of VV mice
815 tested by the same treadmill protocol. Any mice that did not finish the protocol were excluded
816 from subsequent sample collection. After exercise, the mice were allowed to rest for 3 hours with
817 access to water but not food. Then they were euthanized by cervical dislocation after being

818 anesthetized by isoflurane. The quadriceps muscles were quickly excised, frozen, and stored in
819 liquid nitrogen.

820

821 **RNA extraction, quantification and quality control**

822 To extract high quality total RNA, the quadriceps muscles were processed first in the Trizol
823 reagent (ThermoFisher Scientific, Catalog # 15596018) and then purified by RNeasy mini
824 columns (Qiagen, catalog # 74104) as follows. To avoid sampling bias, the entire quadriceps
825 muscles were homogenized in Trizol reagent at the weight (mg) to volume (μL) ratio of 1:15.
826 One mL of homogenate was processed following the manufacture's protocol until the step of
827 phase separation. Then, 0.5 mL of the aqueous phase was mixed with an equal volume of 70%
828 ethanol for subsequent RNA purification by RNeasy mini kit (Qiagen, catalog # 74104) with on-
829 column DNase (RNase-Free DNase Set, Qiagen catalog # 79254) treatment. The concentration
830 of the RNA was determined by Qubit fluorometric quantitation (Qubit RNA BR Assay Kit,
831 ThermoFisher Scientific, catalog # Q10210). The integrity of the total RNA was determined by a
832 Fragment Analyzer (Advanced Analytical Technologies, Inc). The average RNA Quality
833 Number (RQN) was 9.04 ± 0.08 (Mean \pm SEM, $n=24$).

834

835 **RNA sequencing library preparation**

836 1 μg of total RNA from each sample was used for RNA sequencing library preparation with the
837 TruSeq® Stranded mRNA Library Prep kit (Illumina, catalog # 20020594). The libraries were
838 barcoded by TruSeq® RNA Unique Dual Indexes (Illumina, catalog # 20022371) and quantified
839 by qPCR on a Bio-Rad CFX Connect Real-Time PCR detection system with the NEBNext
840 Library Quant Kit for Illumina (New England Biolabs, catalog # E7630L). The libraries were
841 normalized to 10 nM, pooled and sequenced.

842

843 **RNA sequencing and data analyses**

844 RNA sequencing was carried out at Johns Hopkins School of Medicine Genetic Resources Core
845 Facility on a NovaSeq 6000 sequencing system (Illumina) with a S1 flow cell for 200 cycles,
846 generating 100 bp paired-end reads. Sequencing data processing was carried out by the Johns
847 Hopkins Computational Biology Consulting Core. The statistics for sequencing data analysis are
848 presented in supplementary tables 1-3. The RNA sequencing data were submitted to GEO
849 repository and were assigned record number GSE132520.

850

851 Biological interpretation of sequencing results was carried out with the Ingenuity Pathway
852 Analysis (IPA) platform (QIAGEN Ingenuity Systems, Redwood CA, USA) at the Johns
853 Hopkins Deep Sequencing & Microarray Core Facility. The differentially expressed genes (over
854 2σ) between exercised and sedentary groups within the same genotypes and between the MM
855 and VV samples after exercise were mapped by IPA to known pathways and biological functions
856 of a curated Knowledge Base (QIAGEN Bioinformatics IPA Winter Release 2018). IPA
857 evaluated the statistical significance of over-representation of the differentially expressed genes
858 in each pathway or biological function, and a P -value < 0.05 was defined as statistically
859 significant. In addition, IPA calculated the whether a pathway or biological function can be
860 considered activated ($z \geq 2.0$), inactivated ($z \leq -2.0$) or bidirectional altered ($-2.0 < z < 2.0$)
861 based the up- and down-regulation of genes involved the pathway or biological function.

862

863 RT-qPCR

864 For samples from mice, we converted 1 µg of total RNA from each sample into cDNA with the
865 iScript™ Reverse Transcription Supermix (Bio-Rad, Hercules, CA catalog # 1708840). 2 ng of
866 cDNA were used in each qPCR reaction on a CFX Connect Real-time PCR detection system
867 (Bio-Rad, Hercules, CA) with SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad,
868 Hercules, CA catalog # 1725271). The primers for *CaMK2b* (qMmuCID0021273), *CaMK2d*
869 (qMmuCIP0030149), and *CaMK2g* (qMmuCIP0030022) were pre-validated primePCR primers
870 from Bio-Rad. The *Camk2a* primers (AGGTGTGTGAAGGTGCTGG, and
871 TGGAGTCGGACGATATTGGG) were designed with NCBI primer design tool
872 (<https://www.ncbi.nlm.nih.gov/tools/primer-blast/>) and validated in house to recognize all
873 splicing variants containing the kinase domain. qPCR data were analysed by the software Bio-
874 Rad CFX Manager 3.1, using *Gapdh* expression as the loading control.

875
876 For flies, the total RNA from adults was prepared with Direct-Zol RNA miniprep kit with on-
877 column DNase treatment (ZYMO Research, #2050). cDNA synthesis and qPCR were carried out
878 as described above. The primers for qPCR were obtained from the FlyPrimerBank⁶¹ and were
879 further validated for efficiency and specificity. Expression of RP49 was used for normalization.
880 The primer IDs and sequences are as follows: RP49 (PD41810:
881 AGCATACAGGCCCAAGATCG, TGTGTGTCGATACCCTTGGGC), Thor (PD43730:
882 CAGATGCCCGAGGTGTACTC, CATGAAAGCCCGCTCGTAGA), Sulfiredoxin/CG6762
883 (PD42226: GCATCGATGAGACCCACCTG, GATCCACAGCAGGTTCGATGG), Gadd45
884 (PD42384: GGCCTTTTGCTACGAGAACG, CGCAGTAGTCGACTAGCTGG), Socs36E
885 (PP11279: ATGGGTCATCACCTTAGCAAGT, TCCAGGCTGATCGTCTCTACT), GstD2
886 (PP27238: AAACCGCGTTTGGATTTCTCG, GTGGAGACAGTGGACAGGAT), Ank2
887 (PD41602: TGTGGTCATGTTAGGGTGGC, TTCAAAGCCCTTGCATTGGC), Kay
888 (PA60087: ACTCCAACGCTTCGTACAACGATA, CACTTGAAGTATCGGTTCGTGTC), Lk6
889 (PA60203: CAAACGCCAGTAACATC, GCTGTAGGACCACACGCTTGAC), Atf3
890 (PP9314: AAGACGCCAGAGATCCTCAAC, GCAACTGGAATGACTGCTGTC), Drep3
891 (PP34108: GACGATGGTTTGGACGATGC, TGTTCTCGTGATGTCCTTGA), Htk (PP1052:
892 TACCTGGTACATTACACAGGCT, GTGCGAGTTTTCTGCTTGGA), SNF4A γ (PP10614:
893 ACCTCCGCCAAGTTGGTTG, CGCACACCGTTGTAGACGA), Sra (PP5475:
894 CCGATGCACCTGATCCGAC, TTGTTCTTGCTTCTGCCGTTG), Axud1 (PP35701:
895 GAGATAATCGTACTAGGCGATGC, GCGGAGTCAAGAATGTTGTCAA).

896

897 **Supplementary table 1 | Statistics of differential expression analysis by Cuffdiff2**
 898

#Categories	MM (sed) vs. VV (sed)	MM (ex) vs. VV (ex)	MM (sed) vs. MM (ex)	VV (sed) vs. VV (ex)
(1) gene_exp.diff	30529	30599	30598	30618
(2) OK	14628	14689	14825	14628
(3) signif	93	96	743	324
(4) signif.ann	41	46	582	216
(5) signif.ann.fpkm2	40	41	490	194
(6) signif.ann.fpkm2.logFC1.5	0	3	34	24
(7) signif.ann.fpkm5	33	31	365	157
(8) signif.ann.fpkm5.logFC1.5	0	3	26	21
(9) signif.novel	52	50	161	108
(10) signif.novel.fpkm2	29	27	77	44
(11) signif.novel.fpkm2.logFC1.5	20	25	47	33

899 # (1) Number of loci; (2) Testable loci; (3) Significant genes ($P\text{-val} \leq 0.05$, $q\text{-val} \leq 0.05$); (4)
 900 Significant and annotated (known) genes; of which: (5) at least one of FPKM1 and FPKM2 \geq
 901 2.0; (6) additionally, log2 fold change ≥ 1.5 ; (7) at least one of FPKM1 and FPKM2 ≥ 5.0 ; (8)
 902 additionally, log2 fold change ≥ 1.5 ; (9) Significant and unannotated ('novel') loci; of which:
 903 (10) at least one of FPKM1 and FPKM2 ≥ 2.0 ; (11) additionally, log2 fold change ≥ 1.5 .
 904

905
906
907

Supplementary table 2 | Alignment statistics of RNA sequencing reads[#]

Sample	InputReads	Aligned (R1+R2)	(R1+R2)%	Concordant%
VV1 (sed)	41,945,048	39,070,968	93.1	91.90%
VV2 (sed)	42,016,122	38,807,529	92.3	91.00%
VV3 (sed)	46,189,514	41,951,595	90.8	89.40%
VV4 (sed)	43,144,230	39,254,593	90.9	89.60%
VV5 (ex)	47,807,944	42,458,900	88.8	87.30%
VV6 (ex)	38,539,280	35,076,702	91.0	89.60%
VV7 (ex)	49,663,280	44,645,070	89.8	87.90%
VV8 (ex)	49,188,874	44,338,048	90.1	88.80%
MM1 (sed)	46,952,868	43,008,663	91.5	90.20%
MM2 (sed)	46,419,456	41,927,251	90.3	88.90%
MM3 (sed)	41,815,766	39,202,326	93.7	92.50%
MM4 (sed)	48,554,206	45,274,822	93.2	91.90%
MM5 (ex)	42,053,606	38,226,221	90.8	89.50%
MM6 (ex)	39,374,142	36,293,822	92.1	90.90%
MM7 (ex)	50,489,586	46,161,870	91.4	90.20%
MM8 (ex)	47,541,966	43,658,172	91.8	90.60%

908 [#] Reads were aligned with Tophat2.

909
910
911

912 **Supplementary table 3 | RNA sequencing read classification**

Sample	Aligned	Intergenic	Intron	Exon	Exon-intron	(Ex+Ex-in) %
VV1 (sed)	39,070,968	10,871,032	1,151,817	20,572,924	6,475,195	69.2
VV2 (sed)	38,807,529	10,173,751	1,056,398	20,822,770	6,754,610	71.1
VV3 (sed)	41,951,595	9,850,891	1,100,707	23,295,361	7,704,636	73.9
VV4 (sed)	39,254,593	9,358,135	1,067,585	21,523,146	7,305,727	73.4
VV5 (ex)	42,458,900	9,795,942	1,104,903	23,546,149	8,011,906	74.3
VV6 (ex)	35,076,702	8,350,481	1,020,203	19,380,828	6,325,190	73.3
VV7 (ex)	44,645,070	12,762,540	1,450,013	22,758,083	7,674,434	68.2
VV8 (ex)	44,338,048	12,196,685	1,273,665	23,333,460	7,534,238	69.6
MM1 (sed)	43,008,663	14,389,489	1,223,644	20,909,218	6,486,312	63.7
MM2 (sed)	41,927,251	11,612,157	1,202,400	22,166,915	6,945,779	69.4
MM3 (sed)	39,202,326	9,690,241	1,091,394	21,601,873	6,818,818	72.5
MM4 (sed)	45,274,822	11,798,947	1,183,309	24,310,729	7,981,837	71.3
MM5 (ex)	38,226,221	9,375,367	1,089,510	20,889,204	6,872,140	72.6
MM6 (ex)	36,293,822	9,136,213	1,069,954	19,752,989	6,334,666	71.9
MM7 (ex)	46,161,870	12,957,951	1,406,060	24,129,718	7,668,141	68.9
MM8 (ex)	43,658,172	12,897,911	1,309,884	22,353,997	7,096,380	67.5

913
914
915
916

917
918
919
920

References

- 921 1 Anderson, M. E., Brown, J. H. & Bers, D. M. CaMKII in myocardial hypertrophy and
922 heart failure. *J Mol Cell Cardiol* **51**, 468-473, doi:10.1016/j.yjmcc.2011.01.012 (2011).
- 923 2 Erickson, J. R. *et al.* A dynamic pathway for calcium-independent activation of CaMKII
924 by methionine oxidation. *Cell* **133**, 462-474, doi:10.1016/j.cell.2008.02.048 (2008).
- 925 3 Erickson, J. R. *et al.* Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-
926 linked glycosylation. *Nature* **502**, 372-376, doi:10.1038/nature12537 C2 - PMC3801227
927 (2013).
- 928 4 Lou, L. L., Lloyd, S. J. & Schulman, H. Activation of the multifunctional
929 Ca²⁺/calmodulin-dependent protein kinase by autophosphorylation: ATP modulates
930 production of an autonomous enzyme. *Proc Natl Acad Sci U S A* **83**, 9497-9501 (1986).
- 931 5 Miller, S. G. & Kennedy, M. B. Regulation of brain type II Ca²⁺/calmodulin-dependent
932 protein kinase by autophosphorylation: a Ca²⁺-triggered molecular switch. *Cell* **44**, 861-
933 870 (1986).
- 934 6 Purohit, A. *et al.* Oxidized Ca(2+)/calmodulin-dependent protein kinase II triggers atrial
935 fibrillation. *Circulation* **128**, 1748-1757, doi:10.1161/CIRCULATIONAHA.113.003313
936 (2013).
- 937 7 Luo, M. *et al.* Diabetes increases mortality after myocardial infarction by oxidizing
938 CaMKII. *J Clin Invest* **123**, 1262-1274, doi:10.1172/JCI65268 (2013).
- 939 8 Hart, P. C. *et al.* MnSOD upregulation sustains the Warburg effect via mitochondrial
940 ROS and AMPK-dependent signalling in cancer. *Nat Commun* **6**, 6053,
941 doi:10.1038/ncomms7053 (2015).
- 942 9 Sanders, P. N. *et al.* CaMKII is essential for the proasthmatic effects of oxidation.
943 *Science Translational Medicine* **5**, 195ra197, doi:10.1126/scitranslmed.3006135 C2 -
944 PMC4331168 (2013).
- 945 10 Gu, S. X. *et al.* Protein methionine oxidation augments reperfusion injury in acute
946 ischemic stroke. *JCI Insight* **1**, doi:10.1172/jci.insight.86460 (2016).
- 947 11 Qu, J. *et al.* Oxidized CaMKII promotes asthma through the activation of mast cells. *JCI*
948 *Insight* **2**, e90139, doi:10.1172/jci.insight.90139 (2017).
- 949 12 Swaminathan, P. D. *et al.* Oxidized CaMKII causes cardiac sinus node dysfunction in
950 mice. *J Clin Invest* **121**, 3277-3288, doi:10.1172/JCI57833 (2011).
- 951 13 Wu, Y., Wang, Q., Feng, N., Granger, J. M. & Anderson, M. E. Myocardial death and
952 dysfunction after ischemia-reperfusion injury require CaMKII δ oxidation. *Sci Rep* **9**,
953 9291, doi:10.1038/s41598-019-45743-6 (2019).
- 954 14 Bus, J. S. & Gibson, J. E. Paraquat: model for oxidant-initiated toxicity. *Environ Health*
955 *Perspect* **55**, 37-46, doi:10.1289/ehp.845537 (1984).
- 956 15 Gee, H. *Across the bridge : understanding the origin of the vertebrates.* (The University
957 of Chicago Press, 2018).
- 958 16 Green, S. A., Simoes-Costa, M. & Bronner, M. E. Evolution of vertebrates as viewed
959 from the crest. *Nature* **520**, 474-482, doi:10.1038/nature14436 (2015).
- 960 17 Rose, A. J., Alsted, T. J., Kobbero, J. B. & Richter, E. A. Regulation and function of
961 Ca²⁺-calmodulin-dependent protein kinase II of fast-twitch rat skeletal muscle. *J Physiol*
962 **580**, 993-1005, doi:10.1113/jphysiol.2006.127464 (2007).

- 963 18 Tavi, P. *et al.* Calmodulin kinase modulates Ca²⁺ release in mouse skeletal muscle. *J*
964 *Physiol* **551**, 5-12, doi:10.1113/jphysiol.2003.042002 (2003).
- 965 19 Regot, S., Hughey, J. J., Bajar, B. T., Carrasco, S. & Covert, M. W. High-sensitivity
966 measurements of multiple kinase activities in live single cells. *Cell* **157**, 1724-1734,
967 doi:10.1016/j.cell.2014.04.039 C2 - PMC4097317 (2014).
- 968 20 Morioka, E., Kanda, Y., Koizumi, H., Miyamoto, T. & Ikeda, M. Histamine Regulates
969 Molecular Clock Oscillations in Human Retinal Pigment Epithelial Cells via H-1
970 Receptors. *Frontiers in Endocrinology* **9**, doi:ARTN 108
971 10.3389/fendo.2018.00108 (2018).
- 972 21 Hanson, P. I., Meyer, T., Stryer, L. & Schulman, H. Dual role of calmodulin in
973 autophosphorylation of multifunctional CaM kinase may underlie decoding of calcium
974 signals. *Neuron* **12**, 943-956 (1994).
- 975 22 Chang, B. H., Mukherji, S. & Soderling, T. R. Characterization of a calmodulin kinase II
976 inhibitor protein in brain. *Proc Natl Acad Sci U S A* **95**, 10890-10895,
977 doi:10.1073/pnas.95.18.10890 (1998).
- 978 23 Shen, T. *et al.* DNA binding sites target nuclear NFATc1 to heterochromatin regions in
979 adult skeletal muscle fibers. *Histochem Cell Biol* **134**, 387-402, doi:10.1007/s00418-010-
980 0744-4 (2010).
- 981 24 Noble, B. J., Borg, G. A., Jacobs, I., Ceci, R. & Kaiser, P. A category-ratio perceived
982 exertion scale: relationship to blood and muscle lactates and heart rate. *Med Sci Sports*
983 *Exerc* **15**, 523-528 (1983).
- 984 25 Fan, W. *et al.* PPARdelta Promotes Running Endurance by Preserving Glucose. *Cell*
985 *Metab* **25**, 1186-1193 e1184, doi:10.1016/j.cmet.2017.04.006 (2017).
- 986 26 Ozcan, L. *et al.* Calcium signaling through CaMKII regulates hepatic glucose production
987 in fasting and obesity. *Cell Metabolism* **15**, 739-751, doi:10.1016/j.cmet.2012.03.002 C2
988 - PMC3348356 (2012).
- 989 27 Holloszy, J. O. & Kohrt, W. M. Regulation of carbohydrate and fat metabolism during
990 and after exercise. *Annu Rev Nutr* **16**, 121-138,
991 doi:10.1146/annurev.nu.16.070196.001005 (1996).
- 992 28 Iyer, S. R., Valencia, A. P., Hernandez-Ochoa, E. O. & Lovering, R. M. In Vivo
993 Assessment of Muscle Contractility in Animal Studies. *Methods in molecular biology*
994 *(Clifton, N.J.)* **1460**, 293-307, doi:10.1007/978-1-4939-3810-0_20 (2016).
- 995 29 Liu, Y., Hernandez-Ochoa, E. O., Randall, W. R. & Schneider, M. F. NOX2-dependent
996 ROS is required for HDAC5 nuclear efflux and contributes to HDAC4 nuclear efflux
997 during intense repetitive activity of fast skeletal muscle fibers. *Am J Physiol Cell Physiol*
998 **303**, C334-347, doi:10.1152/ajpcell.00152.2012 (2012).
- 999 30 Allen, D. G., Lamb, G. D. & Westerblad, H. Skeletal muscle fatigue: cellular
1000 mechanisms. *Physiological Reviews* **88**, 287-332, doi:10.1152/physrev.00015.2007
1001 (2008).
- 1002 31 Jackson, S. H., Gallin, J. I. & Holland, S. M. The p47phox mouse knock-out model of
1003 chronic granulomatous disease. *J Exp Med* **182**, 751-758 (1995).
- 1004 32 Khairallah, R. J. *et al.* Microtubules underlie dysfunction in duchenne muscular
1005 dystrophy. *Sci Signal* **5**, ra56, doi:10.1126/scisignal.2002829 (2012).
- 1006 33 Powers, S. K., Talbert, E. E. & Adhietty, P. J. Reactive oxygen and nitrogen species as
1007 intracellular signals in skeletal muscle. *J Physiol* **589**, 2129-2138,
1008 doi:10.1113/jphysiol.2010.201327 (2011).

- 1009 34 Prosser, B. L., Khairallah, R. J., Ziman, A. P., Ward, C. W. & Lederer, W. J. X-ROS
1010 signaling in the heart and skeletal muscle: stretch-dependent local ROS regulates
1011 [Ca(2+)]_i. *J Mol Cell Cardiol* **58**, 172-181, doi:10.1016/j.yjmcc.2012.11.011 (2013).
- 1012 35 Chin, E. R. The role of calcium and calcium/calmodulin-dependent kinases in skeletal
1013 muscle plasticity and mitochondrial biogenesis. *The Proceedings of the Nutrition Society*
1014 **63**, 279-286, doi:10.1079/PNS2004335 (2004).
- 1015 36 Egan, B. & Zierath, J. R. Exercise metabolism and the molecular regulation of skeletal
1016 muscle adaptation. *Cell Metabolism* **17**, 162-184, doi:10.1016/j.cmet.2012.12.012 (2013).
- 1017 37 Kramer, A., Green, J., Pollard, J., Jr. & Tugendreich, S. Causal analysis approaches in
1018 Ingenuity Pathway Analysis. *Bioinformatics* **30**, 523-530,
1019 doi:10.1093/bioinformatics/btt703 (2014).
- 1020 38 Peake, J., Nosaka, K. & Suzuki, K. Characterization of inflammatory responses to
1021 eccentric exercise in humans. *Exerc Immunol Rev* **11**, 64-85 (2005).
- 1022 39 Ling, H. *et al.* Ca²⁺/Calmodulin-dependent protein kinase II delta mediates myocardial
1023 ischemia/reperfusion injury through nuclear factor-kappaB. *Circ Res* **112**, 935-944,
1024 doi:10.1161/CIRCRESAHA.112.276915 (2013).
- 1025 40 Singh, M. V. *et al.* Ca²⁺/calmodulin-dependent kinase II triggers cell membrane injury
1026 by inducing complement factor B gene expression in the mouse heart. *J Clin Invest* **119**,
1027 986-996, doi:10.1172/JCI35814 (2009).
- 1028 41 Suetomi, T. *et al.* Inflammation and NLRP3 Inflammasome Activation Initiated in
1029 Response to Pressure Overload by Ca(2+)/Calmodulin-Dependent Protein Kinase II delta
1030 Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling. *Circulation*
1031 **138**, 2530-2544, doi:10.1161/CIRCULATIONAHA.118.034621 (2018).
- 1032 42 Cai, B. *et al.* MerTK signaling in macrophages promotes the synthesis of inflammation
1033 resolution mediators by suppressing CaMKII activity. *Sci Signal* **11**,
1034 doi:10.1126/scisignal.aar3721 (2018).
- 1035 43 Liu, X. *et al.* CaMKII promotes TLR-triggered proinflammatory cytokine and type I
1036 interferon production by directly binding and activating TAK1 and IRF3 in macrophages.
1037 *Blood* **112**, 4961-4970, doi:10.1182/blood-2008-03-144022 (2008).
- 1038 44 Huang, W., Ghisletti, S., Perissi, V., Rosenfeld, M. G. & Glass, C. K. Transcriptional
1039 integration of TLR2 and TLR4 signaling at the NCoR derepression checkpoint. *Mol Cell*
1040 **35**, 48-57, doi:10.1016/j.molcel.2009.05.023 (2009).
- 1041 45 Huang, W. *et al.* Coronin 2A mediates actin-dependent de-repression of inflammatory
1042 response genes. *Nature* **470**, 414-418, doi:10.1038/nature09703 (2011).
- 1043 46 Bui, J. D. *et al.* A Role for CaMKII in T Cell Memory. *Cell* **100**, 457-467,
1044 doi:10.1016/s0092-8674(00)80681-9 (2000).
- 1045 47 Peckham, M., Molloy, J. E., Sparrow, J. C. & White, D. C. Physiological properties of
1046 the dorsal longitudinal flight muscle and the tergal depressor of the trochanter muscle of
1047 *Drosophila melanogaster*. *J Muscle Res Cell Motil* **11**, 203-215 (1990).
- 1048 48 Reiner, D. J., Newton, E. M., Tian, H. & Thomas, J. H. Diverse behavioural defects
1049 caused by mutations in *Caenorhabditis elegans* unc-43 CaM kinase II. *Nature* **402**, 199-
1050 203, doi:10.1038/46072 (1999).
- 1051 49 Brown, J. B. *et al.* Diversity and dynamics of the *Drosophila* transcriptome. *Nature* **512**,
1052 393-399, doi:10.1038/nature12962 (2014).

- 1053 50 Kumar, S., Stecher, G., Suleski, M. & Hedges, S. B. TimeTree: A Resource for
1054 Timelines, Timetrees, and Divergence Times. *Mol Biol Evol* **34**, 1812-1819,
1055 doi:10.1093/molbev/msx116 (2017).
- 1056 51 Backs, J., Song, K., Bezprozvannaya, S., Chang, S. & Olson, E. N. CaM kinase II
1057 selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. *The*
1058 *Journal of Clinical Investigation* **116**, 1853-1864, doi:10.1172/JCI27438 C2 -
1059 PMC1474817 (2006).
- 1060 52 Ryder, E. *et al.* The DrosDel collection: a set of P-element insertions for generating
1061 custom chromosomal aberrations in *Drosophila melanogaster*. *Genetics* **167**, 797-813,
1062 doi:10.1534/genetics.104.026658 (2004).
- 1063 53 Kumar, S., Stecher, G., Li, M., Knyaz, C. & Tamura, K. MEGA X: Molecular
1064 Evolutionary Genetics Analysis across Computing Platforms. *Mol Biol Evol* **35**, 1547-
1065 1549, doi:10.1093/molbev/msy096 (2018).
- 1066 54 Bloemberg, D. & Quadriatero, J. Rapid determination of myosin heavy chain expression
1067 in rat, mouse, and human skeletal muscle using multicolor immunofluorescence analysis.
1068 *PLoS One* **7**, e35273, doi:10.1371/journal.pone.0035273 (2012).
- 1069 55 Vogler, G. & Ocorr, K. Visualizing the beating heart in *Drosophila*. *J Vis Exp*,
1070 doi:10.3791/1425 (2009).
- 1071 56 Fink, M. *et al.* A new method for detection and quantification of heartbeat parameters in
1072 *Drosophila*, zebrafish, and embryonic mouse hearts. *Biotechniques* **46**, 101-113,
1073 doi:10.2144/000113078 (2009).
- 1074 57 Cammarato, A., Ocorr, S. & Ocorr, K. Enhanced assessment of contractile dynamics in
1075 *Drosophila* hearts. *Biotechniques* **58**, 77-80, doi:10.2144/000114255 (2015).
- 1076 58 Rizzo, M. A., Springer, G. H., Granada, B. & Piston, D. W. An improved cyan
1077 fluorescent protein variant useful for FRET. *Nat Biotechnol* **22**, 445-449,
1078 doi:10.1038/nbt945 (2004).
- 1079 59 McQuin, C. *et al.* CellProfiler 3.0: Next-generation image processing for biology. *PLoS*
1080 *Biol* **16**, e2005970, doi:10.1371/journal.pbio.2005970 (2018).
- 1081 60 Cohen, T. V., Kollias, H. D., Liu, N., Ward, C. W. & Wagner, K. R. Genetic disruption
1082 of Smad7 impairs skeletal muscle growth and regeneration. *J Physiol* **593**, 2479-2497,
1083 doi:10.1113/JP270201 (2015).
- 1084 61 Hu, Y. *et al.* FlyPrimerBank: an online database for *Drosophila melanogaster* gene
1085 expression analysis and knockdown evaluation of RNAi reagents. *G3 (Bethesda, Md.)* **3**,
1086 1607-1616, doi:10.1534/g3.113.007021 (2013).
- 1087